FATE
Price:
$2.71
Market Cap:
$308.61M
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the ...[Read more]
Industry
Biotechnology
IPO Date
2013-10-01
Stock Exchange
NASDAQ
Ticker
FATE
According to Fate Therapeutics, Inc.’s latest financial reports and current stock price. The company's current ROE is -44.09%. This represents a change of 299.57% compared to the average of -11.03% of the last 4 quarters.
The mean historical ROE of Fate Therapeutics, Inc. over the last ten years is -52.41%. The current -44.09% ROE has changed -15.87% with respect to the historical average. Over the past ten years (40 quarters), FATE's ROE was at its highest in in the March 2023 quarter at -1.92%. The ROE was at its lowest in in the June 2018 quarter at -37.92%.
Average
-52.41%
Median
-45.02%
Minimum
-91.33%
Maximum
-30.39%
Discovering the peaks and valleys of Fate Therapeutics, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 122.26%
Maximum Annual ROE = -30.39%
Minimum Annual Increase = -41.99%
Minimum Annual ROE = -91.33%
Year | ROE | Change |
---|---|---|
2023 | -43.68% | -17.12% |
2022 | -52.70% | 73.42% |
2021 | -30.39% | -31.40% |
2020 | -44.30% | 10.96% |
2019 | -39.92% | -3.81% |
2018 | -41.50% | -25.42% |
2017 | -55.65% | 21.65% |
2016 | -45.74% | -41.99% |
2015 | -78.85% | -13.67% |
2014 | -91.33% | 122.26% |
The current ROE of Fate Therapeutics, Inc. (FATE) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-42.26%
5-year avg
-42.20%
10-year avg
-52.41%
Fate Therapeutics, Inc.’s ROE is less than Atara Biotherapeutics, Inc. (2.02%), greater than Sana Biotechnology, Inc. (-71.60%), greater than Caribou Biosciences, Inc. (-34.76%), greater than Arcus Biosciences, Inc. (-42.86%), greater than Intellia Therapeutics, Inc. (-49.70%), greater than Editas Medicine, Inc. (-62.61%), greater than CRISPR Therapeutics AG (-13.85%), greater than Verve Therapeutics, Inc. (-35.20%), greater than Theseus Pharmaceuticals, Inc. (-24.51%), greater than aTyr Pharma, Inc. (-56.83%), greater than Relay Therapeutics, Inc. (-43.66%), greater than Century Therapeutics, Inc. (-65.37%), greater than Blueprint Medicines Corporation (-47.66%), greater than Beam Therapeutics Inc. (-16.22%), greater than Prime Medicine, Inc. (-113.34%),
Company | ROE | Market cap |
---|---|---|
2.02% | $64.85M | |
-71.60% | $843.15M | |
-34.76% | $214.16M | |
-42.86% | $1.42B | |
-49.70% | $1.55B | |
-62.61% | $242.07M | |
-13.85% | $4.31B | |
-35.20% | $517.90M | |
-24.51% | $181.50M | |
-56.83% | $131.12M | |
-43.66% | $959.33M | |
-65.37% | $108.01M | |
-47.66% | $5.84B | |
-16.22% | $2.04B | |
-113.34% | $481.31M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Fate Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Fate Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Fate Therapeutics, Inc.'s ROE?
How is the ROE calculated for Fate Therapeutics, Inc. (FATE)?
What is the highest ROE for Fate Therapeutics, Inc. (FATE)?
What is the 3-year average ROE for Fate Therapeutics, Inc. (FATE)?
What is the 5-year average ROE for Fate Therapeutics, Inc. (FATE)?
How does the current ROE for Fate Therapeutics, Inc. (FATE) compare to its historical average?